



21 September 2020

## **Opyl strengthens its Board and Management**

**Melbourne, Australia, 21<sup>st</sup> of September 2020**, Opyl Ltd (ASX:OPL) today announces the appointment of Mr Mark Ziirsen to the Opyl Board effective from today. Mark will also immediately become the new Opyl chair of the Audit and Risk Committee taking over from Mr Damon Rasheed who will step into an executive director role leverage his expertise in the Artificial Intelligence space, particularly in relation to the Opyl Clinical Trial Predictor Tool.

Opyl Chairman, Dr Julian Chick, said: "We are delighted to welcome Mark to the Board, as he brings a wealth of financial and commercial experience in the health sector. Mark's expertise and networks will complement the Opyl leadership team, particularly as we extend our footprint."

Mark is an experienced ASX listed, non-executive director and CFO. He served as non-executive director and chair of Respire Limited, an eHealth SaaS company supporting respiratory health management, and as non-executive director and chair of the Audit and Risk Committee of Orcoda Limited, a SaaS-based technology company. His executive career includes senior finance leadership roles with major ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited.

He commenced his career with EY in business advisory, tax and management consulting. Most recently, he was CFO and company secretary for Wiseway Group Limited where he successfully led the company through an IPO, listing on ASX. Immediately prior to that he was CFO of listed global medtech company Anteris Technologies Limited and before that, Director of Finance and IT for Asia Pacific at hearing implant maker Cochlear Limited.

Mark has a strong track record in delivering growth and operational improvement across multiple industry sectors (medtech/health, technology, consumer) and geographies, having worked extensively in Asia for more than 25 years. His strong finance and operations credentials are complemented by extensive corporate finance, governance, risk management, strategy, M&A and investor relations skills. Much of Mark's work has involved guiding high growth and early stage companies.

Mark's qualifications include a Bachelor of Commerce, CPA designation and an MBA majoring in international business. He is also a member of the Australian Institute of Company Directors.

In accepting the board position Mark said: "Opyl has a significant opportunity to evolve and further commercialise its technology platforms and I understand the capability and global opportunity for the company. It is with great excitement and determination that I join the Opyl board to assist in making a significant contribution to the ongoing growth of the business."

With the recent priority focus on accelerating the development of the Opyl Clinical Trial Predictor Tool, Damon is taking a more active role in supporting the advancement of technologies within the company, leveraging his expertise in AI.

The Board has authorised this announcement for release to the ASX.

**-ENDS-**



For media enquiries: Laura Blue +61 416 699 925  
For investor enquiries: [info@opyl.ai](mailto:info@opyl.ai)  
[www.opyl.ai](http://www.opyl.ai)

Opyl is a new generation Australian company that provides leading biopharma and health organisations access to emerging AI-assisted technologies and real-world data insights to understand and improve healthcare design, development and delivery.

Opyl works at the intersection of clinical trials, artificial intelligence and social media.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment and retention solutions
- clinical trial predictive analytics
- deep social media insights

Our vision is to improve health and wellness by optimising data assets and digital activation to advance technologies for life.

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook